This market study on
Bacteriophages Therapy Market covers The market study conducted in this report analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors in the industry. Also, it sheds light on the wide-ranging competitive landscape of the global Bacteriophages Therapy market. It defines about the recent innovations, applications and end users of the market.The report first introduces the market basics like definitions, classifications, applications, and industry chain overview, and then industry policies and plans, product specifications, manufacturing processes, cost structures, and so on. The challenges led by the COVID-19 pandemic, leading to a decline in demand, and several initiatives taken by the government are studied in this report. The wide range of end-use applications, Heat Pumps major types, revenue, and distributors are stated. The regional analysi
Pherecydes Pharma Lists On Euronext Growth Paris To Accelerate Its Fight Against Antibiotic-Resistant Bacteria Date
05/02/2021
Euronext today congratulates Pherecydes Pharma, the French biotech company specialising in the treatment of bacterial infections, especially those that are complicated and/or resistant to antibiotics, on its listing on Euronext Growth Paris (ticker code: ALPHE).
Pherecydes Pharma was created in 2006. Its headquarters are in Nantes, and its research and development centre is based in Romainville. The company develops treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections that do not respond to antibiotic treatment. According to the World Health Organisation, antibiotic resistance could be responsible for more than 10 million deaths per year by 2050[1]. The capital raised will allow Pherecydes Pharma to conduct further clinical tests and potentially to make the medicines available through temporary authorisations
Resounding Success of Pherecydes Pharma s IPO on the Euronext Growth Market in Paris
Offer oversubscribed 4 times, with global demand totaling €28.1 million
Capital increase of approximately €8 million, after full exercise of the Extension Clause
Trading in the Company s shares begins on February 5, 2021 (FR0011651694 ALPHE)
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the resounding success of its initial public offering on the Euronext Growth market in Paris.
Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, says:
I am particularly sensitive to the high level of interest the financial community has shown in our IPO project, both institutional and individual investors. I would like to thank all our shareholders, longstanding and new, who have chosen to accompany us
Share this article
Share this article
ResearchAndMarkets.com s offering.
Antimicrobial Resistance is creating new kinds of infections and superbugs that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market.
We have identified the 6 Key Large Opportunities in this space and developed market forecasts.The publisher has looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play.
This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And the publisher summarizes what technologies they are using.
Bacteriophage Market Analysis: To Reach Around US$ 567.9 Mn In 2027
January 26, 2021 | by admin |
The global bacteriophage market was valued at US$ 567.9 Mn in 2017 expanding at a CAGR of 3.9% from 2018 to 2026.
Market Insights
Recently, bacteriophages or phages have been recognized as an efficient tool in modern biotechnology through a multitude of researches promoting the potential use of bacteriophages across a number of applications. Researchers have also proposed bacteriophages as a viable alternative to antibiotics for a number of antibiotic-resistant bacterial strains. They can also be used as biocontrol agents in the oil and agriculture industries.
Bacteriophages have a unique application in the petroleum industry, as bacterial fouling often leads to serious damage to gas pipelines, devaluing products and therefore increasing capital costs. In addition, bacteriophages may also be used as vaccine vehicles, for the detection of pathogenic bacterial str